

# Laura MelÃ©ndez-Alafort

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7516548/publications.pdf>

Version: 2024-02-01

65  
papers

1,698  
citations

489802

18  
h-index

325983

40  
g-index

71  
all docs

71  
docs citations

71  
times ranked

1783  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis and Preclinical Assessment of $^{99m}\text{Tc}$ -iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging. <i>Molecules</i> , 2022, 27, 264.	1.7	16
2	A feasibility study of the therapeutic application of a mixture of $^{67/64}\text{Cu}$ radioisotopes produced by cyclotrons with proton irradiation. <i>Medical Physics</i> , 2022, 49, 2709-2724.	1.6	10
3	$^{225}\text{Ac}$ -rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins. <i>Molecules</i> , 2022, 27, 2156.	1.7	5
4	Impact of Different [Tc(N)PNP]-Scaffolds on the Biological Properties of the Small cRGDFK Peptide: Synthesis, In Vitro and In Vivo Evaluations. <i>Molecules</i> , 2022, 27, 2548.	1.7	3
5	A Review on the Current State and Future Perspectives of [ $^{99m}\text{Tc}$ ]Tc-Housed PSMA-i in Prostate Cancer. <i>Molecules</i> , 2022, 27, 2617.	1.7	15
6	IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 1060.	2.0	2
7	Drug Delivery Systemsâ€Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2000362.	2.1	11
8	Preliminary dosimetric analysis of DOTA-folate radiopharmaceutical radiolabelled with $^{47}\text{Sc}$ produced through $^{nat}\text{V}(\text{p,x})^{47}\text{Sc}$ cyclotron irradiation. <i>Physics in Medicine and Biology</i> , 2021, 66, 025003.	1.6	12
9	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1197-1210.	4.8	14
10	Bioconjugated technetium carbonyls by transmetalation reaction with zinc derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 37, 127840.	1.0	2
11	New Bioconjugated Technetium and Rhenium Folates Synthesized by Transmetallation Reaction with Zinc Derivatives. <i>Molecules</i> , 2021, 26, 2373.	1.7	2
12	Preclinical dosimetric studies of $^{177}\text{Lu}$ -scFvD2B and comparison with $^{177}\text{Lu}$ -PSMAâ€617 and $^{177}\text{Lu}$ -PSMA endoradiotherapeutic agents. <i>Medical Physics</i> , 2021, 48, 4064-4074.	1.6	3
13	Development of $^{177}\text{Lu}$ -scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen. <i>Scientific Reports</i> , 2020, 10, 9313.	1.6	11
14	Synthesis and preclinical evaluation of the $^{99m}\text{Tc}$ -/ $^{177}\text{Lu}$ -CXCR4-L theranostic pair for in vivo chemokine-4 receptor-specific targeting. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2020, 324, 21-32.	0.7	16
15	Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 7032-7047.	1.2	5
16	$^{177}\text{Lu}$ -Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer. <i>Materials Science and Engineering C</i> , 2019, 105, 110043.	3.8	42
17	Radiation effective dose assessment of [ $^{51}\text{Mn}$ ]- and [ $^{52}\text{Mn}$ ]-chloride. <i>Applied Radiation and Isotopes</i> , 2019, 153, 108805.	0.7	10
18	Internal radiation dose assessment of radiopharmaceuticals prepared with cyclotronâ€produced $^{99m}\text{Tc}$ . <i>Medical Physics</i> , 2019, 46, 1437-1446.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Dual-Targeted Therapy and Molecular Imaging with Radiolabeled Nanoparticles. <i>Ecoproduction</i> , 2019, , 201-219.	0.8	0
20	Experimental setup for light-to-heat NIR conversion measurements of gold nanoparticle solutions. <i>Acta Scientifica Naturalis</i> , 2019, 6, 91-99.	0.0	0
21	[ <sup>99m</sup> Tc][Tc(N)(DASD)(PNP<i>n</i>)] <sup>+&lt;/sup&gt; (DASD =) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 672 Td (1,4 Imaging; Synthesis, Pharmacological and Pharmacokinetic Studies. <i>Journal of Medicinal Chemistry</i>, 2018, 61, 11114-11126.</sup>	2.9	10
22	Radioisotopic purity and imaging properties of cyclotron-produced <sup>99m</sup> Tc using direct <sup>100</sup> Mo(<i>p</i>,2<i>n</i>) reaction. <i>Physics in Medicine and Biology</i> , 2018, 63, 185021.	1.6	17
23	[ <sup>99m</sup> Tc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of I±V <sup>2</sup> <sub>3</sub> Integrin: Synthesis, Structureâ€Activity and Pharmacokinetic Studies. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9596-9610.	2.9	17
24	In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticals. <i>Applied Radiation and Isotopes</i> , 2018, 139, 325-331.	0.7	35
25	Quality assurance of Mo-99/Tc-99m radionuclide generators. <i>Acta Scientifica Naturalis</i> , 2018, 5, 40-47.	0.0	2
26	In vitro cytotoxicity of allelopathic plants <i>Adonis vernalis</i> L. <i>Origanum vulgare</i> ssp. <i>vulgare</i> L. and <i>Nepeta nuda</i> subsp. <i>nuda</i>. <i>Acta Scientifica Naturalis</i> , 2018, 5, 64-69.	0.0	0
27	18th European Symposium on Radiopharmacy and Radiopharmaceuticals. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2016, 1, .	1.8	2
28	A freeze-dried kit formulation for the preparation of Lys 27 ( <sup>99m</sup> Tc-EDDA/HYNIC)-Exendin(9-39)/ <sup>99m</sup> Tc-EDDA/HYNIC-Tyr 3 -Octreotide to detect benign and malignant insulinomas. <i>Nuclear Medicine and Biology</i> , 2015, 42, 911-916.	0.3	6
29	Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with &sup>177&sup>Lu and Conjugated to Peptides. <i>Current Radiopharmaceuticals</i> , 2015, 8, 150-159.	0.3	28
30	Novel [ <sup>99m</sup> Tc<sup>III</sup>(PS) <sub>2</sub> (Ln)] Mixed-Ligand Compounds (PS =) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Agents: Synthesis, in Vitro, and ex Vivo Biodistribution Studies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8960-8970.	2.9	6
31	[ <sup>99m</sup> Tc(N)PNP]-scaffold for SPECT of multidrug resistance: Early in-vitro study. <i>Nuclear Medicine and Biology</i> , 2014, 41, 618.	0.3	0
32	Inhibition of growth and induction of apoptosis in human lung cancer cells by Br-oxph. <i>Genetika</i> , 2014, 46, 1-10.	0.1	4
33	Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 476-499.	0.9	14
34	Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms. <i>Current Pharmaceutical Design</i> , 2012, 18, 1098-1106.	0.9	25
35	New Bioconjugated Rhenium Carbonyls by Transmetalation Reaction with Zinc Derivatives. <i>Organometallics</i> , 2012, 31, 5884-5893.	1.1	11
36	Peptides for In Vivo Target-Specific Cancer Imaging. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 87-97.	1.1	37

#	ARTICLE	IF	CITATIONS
37	Biokinetic and dosimetric studies of <sup>188</sup> Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma. <i>Nuclear Medicine and Biology</i> , 2009, 36, 693-701.	0.3	18
38	Detection of sites of infection in mice using <sup>99m</sup> Tc-labeled PN2S-PEG conjugated to UBI and <sup>99m</sup> Tc-UBI: a comparative biodistribution study. <i>Nuclear Medicine and Biology</i> , 2009, 36, 57-64.	0.3	36
39	Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. <i>Nuclear Medicine and Biology</i> , 2009, 36, 525-533.	0.3	22
40	A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent <i>In vivo</i> Therapeutic Activity. <i>Clinical Cancer Research</i> , 2008, 14, 3598-3606.	3.2	86
41	Simulations and tests for metabolic radiotherapy with <sup>188</sup> Re. <i>Nuclear Physics, Section B, Proceedings Supplements</i> , 2007, 172, 303-307.	0.5	0
42	<sup>188</sup> Rhenium-induced cell death and apoptosis in a panel of tumor cell lines. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2007, 571, 471-474.	0.7	6
43	A YAP camera for the biodistribution of <sup>188</sup> Re conjugated with Hyaluronic-Acid in <i>in vivo</i> systems. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2007, 571, 484-487.	0.7	4
44	Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy. <i>Current Pharmaceutical Analysis</i> , 2006, 2, 339-352.	0.3	28
45	Bioavailability of <sup>99m</sup> Tc-Ha-paclitaxel complex [ <sup>99m</sup> Tc-ONCOFID-P] in mice using four different administration routes. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 939-950.	0.5	16
46	Kit for instant <sup>99m</sup> Tc labeling of the antimicrobial peptide ubiquicidin 29-41. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2005, 266, 307-311.	0.7	13
47	Molecular recognition and stability of <sup>99m</sup> Tc-UBI 29-41 based on experimental and semiempirical results. <i>Applied Radiation and Isotopes</i> , 2004, 61, 1261-1268.	0.7	17
48	Biokinetics of <sup>99m</sup> Tc-UBI 29-41 in humans. <i>Nuclear Medicine and Biology</i> , 2004, 31, 373-379.	0.3	71
49	Preparation via coligand exchange and characterization of [ <sup>99m</sup> Tc-EDDA-HYNIC-D-Phe1,Tyr3]Octreotide ( <sup>99m</sup> Tc-EDDA/HYNIC-TOC). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 307-318.	0.5	31
50	Labeling of biotin with [ <sup>166</sup> Dy]Dy/ <sup>166</sup> Ho as a stable <i>in vivo</i> generator system. <i>International Journal of Pharmaceutics</i> , 2003, 255, 129-138.	2.6	14
51	<i>In vitro</i> and <i>in vivo</i> assessment of <sup>99m</sup> Tc-UBI specificity for bacteria. <i>Nuclear Medicine and Biology</i> , 2003, 30, 597-603.	0.3	66
52	Lys and Arg in UBI: A specific site for a stable Tc- <sup>99m</sup> complex?. <i>Nuclear Medicine and Biology</i> , 2003, 30, 605-615.	0.3	32
53	Optimization of the small-scale synthesis of DOTA-Tyr3-octreotide. <i>Nuclear Medicine Communications</i> , 2002, 23, 493-499.	0.5	5
54	<sup>99m</sup> Tc-glucarate for detection of isoproterenol-induced myocardial infarction in rats. <i>International Journal of Pharmaceutics</i> , 2002, 233, 29-34.	2.6	20

#	ARTICLE	IF	CITATIONS
55	Labelling of Re-ABP with 188Re for bone pain palliation. Applied Radiation and Isotopes, 2001, 54, 435-442.	0.7	15
56	Labelling of octreotide using 76Br-prosthetic groups. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 561-573.	0.5	9
57	<sup>188</sup> Rhenium- <sup>188</sup> labelling of hynic- <sup>3</sup> [Tyr <sup>3</sup> ]octreotide. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S685.	0.5	0
58	<sup>99m</sup> Tc-HYNIC-[Tyr <sup>3</sup> ]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with <sup>111</sup> In-octreotide. Journal of Nuclear Medicine, 2000, 41, 1114-9.	2.8	98
59	A template for defining a causal relation between acute intrapartum events and cerebral palsy: international consensus statement. BMJ: British Medical Journal, 1999, 319, 1054-1059.	2.4	609
60	Labeling peptides with rhenium-188. International Journal of Pharmaceutics, 1999, 182, 165-172.	2.6	14
61	Preparation and Pharmacokinetics of Samarium(III)-153-Labeled DTPA-bis-Biotin. Characterization and Theoretical Studies of the Samarium(III)-152 Conjugate. Bioconjugate Chemistry, 1999, 10, 726-734.	1.8	19
62	Radiopharmacokinetics, Renal Clearance and Dosimetry of <sup>99m</sup> Tc-MAG3. Archives of Medical Research, 1999, 30, 49-54.	1.5	0
63	Preparation, biodistribution, and dosimetry of <sup>188</sup> Re-Labeled MoAb for cea1 and its f(ab <sup>2</sup> ) fragments by avidin-biotin strategy. Nuclear Medicine and Biology, 1999, 26, 57-62.	0.3	22
64	Radiopharmacokinetic data for <sup>99m</sup> Tc-ABP: A new radiopharmaceutical for bone scanning: Comparison with <sup>99m</sup> Tc-MDP. Nuclear Medicine and Biology, 1997, 24, 27-33.	0.3	16
65	Technetium- <sup>99m</sup> -alendronate: a new radiopharmaceutical for bone scanning. Archives of Medical Research, 1996, 27, 481-3.	1.5	3